Lucid Diagnostics (NASDAQ: LUCD) reported second-quarter 2026 financial results showing sequential revenue growth and significant progress in commercial market access. The company recognized $1.5 million in revenue for the quarter, representing a 17 percent increase from the previous quarter’s figure. This top-line performance was driven by the laboratory performing 2,770 EsoGuard tests, which remained within the company’s target range of approximately 2,500 to 3,000 tests per quarter.

A major commercial milestone was achieved with the issuance of the company’s first Laboratory Benefit Manager (LBM) coverage policy by Concert. The policy concluded that EsoGuard is medically necessary for patients meeting established screening criteria. Three of Concert’s client health plans have already adopted this policy, with several more expected to follow. Management noted that securing these regional commercial plans enhances the ability to allocate resources geographically.

Financial Position and Burn Rate

The company maintained a cash balance of $33.4 million as of June 30, which is essentially flat with the year-end balance. This position reflects net proceeds of $16.8 million from a common stock offering completed during the quarter. The quarterly cash burn rate was $11.3 million, slightly lower than the average burn rate of $11.6 million per quarter over the last four periods.

Operating expenses on a non-GAAP basis totaled $12.3 million, in line with the average of $12.2 million for the previous five quarters. The slight increase from the first quarter reflects expected investments in commercial activities, including headcount in sales personnel and clinical service staff. The non-GAAP net loss per share was $(0.06), an improvement of approximately one cent sequentially compared to the prior quarter.

Market Access and Medicare Outlook

Lucid Diagnostics continues to await the publication of a draft Local Coverage Determination (LCD) from Medicare, a milestone expected to impact 40-50 percent of its addressable market. While acknowledging a broad backlog at CMS regarding LCD output, management cited recent signs that the backlog may be loosening, with several long-awaited LCDs posted in recent weeks.

Progress is also being made with the Department of Veterans Affairs (VA). The company has built a robust pipeline of VA centers across the U.S., with clinical engagement described as extremely positive. Contracts for the new federal fiscal year, beginning October 1, are a key focus area. Additionally, preliminary results from a sophisticated cost-effectiveness model developed with American College of Gastroenterology experts are encouraging, showing positive clinical impact compared to current care.

What the Numbers Show

The divergence between test volume and revenue recognition highlights the transitional nature of Lucid’s reimbursement journey. While the company performed 2,770 tests with a billable value exceeding $7.5 million, it recognized only $1.5 million in revenue. This gap exists because revenue for most claims submitted to traditional government or private health insurance is recognized only when collected, due to insufficient predictive data on collection probability under GAAP ASC 606 guidelines. Conversely, revenue from fixed contracts, such as those with employers or the VA, is recognized upon service delivery. This accounting treatment underscores that near-term revenue growth will be heavily influenced by the mix of contracted versus insurance-based testing rather than volume alone.

Note: Q1 figures derived from percentage changes stated in source.

The company’s ability to convert its growing sales base into profitability remains a key focus area, as evidenced by the simultaneous miss on both the revenue and earnings estimates in prior periods. However, the shift toward higher-probability-of-collection channels, such as the VA and contracted events, aims to improve this conversion rate moving forward.

Lucid Diagnostics Inc reported a revenue miss in its first-quarter results, but its top-line is projected to grow significantly in 2026 and 2027, according to Ascendiant Capital analyst Edward Woo. The medical technology company's early commercialization stage currently limits revenue generation, though future growth is anticipated driven by regulatory approvals and expanded coverage. Woo maintained a Buy rating and raised the price target from $9.00 to $9.25, citing significant upside from the current share price.

First-Quarter Performance

Lucid Diagnostics recorded revenue of $1.3 million, falling short of consensus estimates of $1.4 million. The company reported a pro forma net loss of $10.5 million, or 7 cents per share, which was better than the expected loss of 8 cents per share. Operating expenses declined to $12 million, down from $14 million in the previous quarter.

Operational Metrics and Backlog

The company processed 3,177 EsoGuard tests during the first quarter, a decrease from 3,664 tests in the prior quarter but an increase compared to 3,034 tests in the first quarter of 2025. Due to the early stage of its billing and collection process, Lucid Diagnostics defers revenue recognition until cash is collected. Woo estimates there is approximately $40 million in potential test revenue backlog from tests performed but not yet collected.

Commercialization and Future Outlook

Lucid Diagnostics plans to advance the commercialization of its primary products, EsoGuard and EsoCheck, and secure additional regulatory approvals to obtain government coverage. Woo noted that Medicare coverage could be announced soon, which would serve as a catalyst for the stock. The company's focus on expanding coverage and approvals is expected to drive revenue growth in the coming years.